Merck will acquire Terns for $53 per share in cash, amounting to an equity value of about $6.7 billion. This is the third multibillion-dollar acquisition for Merck over the past year as it looks to ...

Merck & Co. agreed to buy Terns Pharmaceuticals Inc. for $6.7 billion, giving the multinational company access to a promising new leukemia treatment as it faces the patent expiration of its ...

Some investors are questioning the premium Merck (MRK) is paying in its $6.7 billion acquisition of Tern Pharmaceuticals (TERN), according to an RBC analyst. Merck agreed to pay $53 a share for Terns ...

Merck MRK-1.03%decrease; red down pointing triangle has reached a nearly $6 billion cash deal to buy the cancer biotech Terns Pharmaceuticals TERN 0.13%increase; green up pointing triangle and its ...

Merck & Co. (MRK) is close to an approximately $6 billion all-cash deal to buy U.S. biotech firm Terns Pharmaceuticals (TERN) as it seeks to boost its drug pipeline ahead of cancer treatment ...

After generating interest from the likes of Pfizer and GSK, Quotient Therapeutics’ somatic genomics platform has attracted another Big Pharma suitor in Merck & Co. Looking to devise new drug targets ...

Merck and Terns Pharmaceuticals have agreed to a $6.7 billion all-cash buyout that delivers a prized leukemia asset to the New Jersey Big Pharma. The crown jewel of the deal is TERN-701, an oral ...

Bloomberg's Michelle Davis joins Dani Burger on "Bloomberg Deals." Merck agreed to buy Terns Pharmaceuticals for $6.7 billion, giving the multinational company access to a promising new leukemia ...

March 24 (Reuters) - Pharmaceutical ⁠company ⁠Merck is nearing ⁠a roughly $6 billion all-cash deal to acquire biotech firm Terns ‌Pharma, the Financial Times ‌reported on Tuesday, citing ⁠people ...

Merck to pay a 6% premium to buy the outstanding shares of Terns Pharmaceuticals, which is developing an oral treatment for leukemia Merck to spend $6.7 billion to buy Terns Pharmaceuticals, which is ...